Biographical Sketch
David Adelstein, MD, is a Staff Physician in the Department of Solid Tumor Oncology in the Taussig Cancer Center, and he is a Professor of Medicine in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He is also Co-Chairman of the Previously Untreated, Locally Advanced Head and Neck Cancer Task Force, a part of the National Cancer Institute Head and Neck Cancer Steering Committee. This group is instrumental in defining the national agenda for clinical investigation in this disease.
Dr. Adelstein completed his undergraduate education at the University of Chicago, his medical school training at New York University School of Medicine, and his internship, residency and hematology/oncology fellowship at Case Western Reserve University Hospitals -- where he served as Chief Medical Resident from 1979-1980.
After his training, he joined the Staff of the Cleveland Metropolitan General Hospital (now MetroHealth Medical Center). He came to the Cleveland Clinic in 1989 to the Department of Hematology and Medical Oncology, where he has served as both Vice-Chairman and Acting Chairman.
Dr. Adelstein is board-certified in internal medicine, hematology and medical oncology. His interests include diagnosis and treatment of cancers of the upper aerodigestive tract, including the head and neck and esophagus. He has focused on the integration of chemotherapy and radiation with surgery in the curative management of these diseases.
He continues to be an active Clinical Investigator, and has conducted a number of multimodality clinical trials within Cleveland Clinic, as well as nationally. He has published widely on the management of aerodigestive tract malignancies in multiple medical journals and currently serves as Associate Editor for the journal Head & Neck.
Specialty Interests
gastrointestinal tumors, head and neck cancer, solid tumor oncology
Industry Relationships
Cleveland Clinic physicians and scientists report if they
have any collaborations with the pharmaceutical or medical
device industries as part of the Cleveland Clinic’s
procedures. The Cleveland Clinic publicly discloses
payments to its physicians and scientists for speaking and
consulting of $5,000 or more per year, and any equity,
royalties, and fiduciary relationships in companies with
which they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its doctors’
connections with industry and those of their immediate
family members. As of 7/30/2008,
Dr. Adelstein has reported no financial relationship with
industry that is applicable to this listing. Patients
should feel free to contact their doctor about
relationships with industry and how the relationships are
overseen by the Cleveland Clinic. To learn more about
the Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to our
Integrity in Innovation page.
